

This work is licensed under a [Creative Commons Attribution-NonCommercial-ShareAlike License](https://creativecommons.org/licenses/by-nc-sa/4.0/). Your use of this material constitutes acceptance of that license and the conditions of use of materials on this site.



Copyright 2006, The Johns Hopkins University and Gary Ketner. All rights reserved. Use of these materials permitted only in accordance with license rights granted. Materials provided "AS IS"; no representations or warranties provided. User assumes all responsibility for use, and all liability related thereto, and must independently review all materials for accuracy and efficacy. May contain materials owned by others. User is responsible for obtaining permissions for use from third parties as needed.



JOHNS HOPKINS
BLOOMBERG
SCHOOL *of* PUBLIC HEALTH

*Host Response to Infection:
The Immune Response and Vaccination*

Gary Ketner, PhD

Johns Hopkins University



JOHNS HOPKINS
BLOOMBERG
SCHOOL *of* PUBLIC HEALTH

Section A

Introduction to Innate Immunity


- Central to survival after infection
- Central to public health
 - Immunity can be manipulated to protect both individuals and populations by vaccination
- Effective use of vaccination depends upon knowledge of immune system function
 - Nature of the vaccine (live, subunit, vectored)
 - Characteristics of the type of immunity induced
 - Target antigens

- Inborn
- Effective without prior exposure to an infectious agent
 - Nonspecific
- “First-line” defense


- Physical barriers
 - Skin
 - Cornea
 - Mucus layers (with clearance)
 - Outflow (urine, for example)
- Chemical barriers
 - Stomach acid
 - Fatty acids on skin
 - Lysozyme in tears
- Active mechanisms
 - Intracellular
 - ▶ Interferons
 - ▶ Apoptosis
 - Organismal
 - ▶ Complement
 - ▶ Phagocytosis

- Active process that destroys invading pathogens
- Mediated by specialized cells (phagocytes)
 - Macrophages, neutrophils
- Phagocytes engulf potential pathogens
 - Efficient engulfment depends on receptors for common bacterial cell wall components
- Once engulfed, pathogens are killed and digested
- Some pathogens are resistant (TB)

- Active process that destroys invading pathogens
- Mediated by specialized cells (phagocytes)
 - Macrophages, neutrophils
- Phagocytes engulf potential pathogens
 - Efficient engulfment depends on receptors for common bacterial cell wall components
- Once engulfed, pathogens are killed and digested



- Phagocytes are located in strategic places
 - Skin, blood, gut
- Phagocytes are **chemotactic** (attracted to sites of injury)
- Phagocytes can be “activated” to become better killers






JOHNS HOPKINS
BLOOMBERG
SCHOOL *of* PUBLIC HEALTH


Section B

Effector Mechanisms of Adaptive Immunity

- Arises as a consequence of exposure to a particular target (virus, protein, toxin)
- Specific for that target
- Arises after a delay of a few days
- Potent
- Exhibits “memory”
 - Rapid, large reappearance upon a second exposure



Adaptive Immunity Primary and Secondary Responses




- **Humoral:** mediated by protein molecules called antibodies
- **Cell-mediated immunity (CMI):** due to the action of specialized immune system cells


- Mediated mostly by protein molecules called **antibodies (Ab)**, also called **immunoglobulin (Ig)**
- Antibodies generally are found in extracellular fluids
 - Blood, lymph, mucus
- Antibodies are active against agents with an extracellular phase, including some viruses, toxins, and bacterial infections
 - Not all pathogens have obligatory extracellular phases
 - ▶ In some cases, extracellular exposure is brief
 - ▶ Antibodies tend to be ineffective against such agents

Antigen Binding by Antibody

- Antibodies act by physically binding to their targets called **antigens (Ag)**
- Antibody binding to antigen occurs because of a close physical fit between the antibody and the target antigen (**epitope**)
 - Binding is extremely specific—a given antibody binds only to one (or a few closely related) antigens
- Binding results in inactivation or destruction of the target




- Four protein chains
 - Two “heavy”
 - Two “light”
 - The heavy chains are identical to each other
 - The light chains are identical to each other
- The chains are held together by disulphide bonds




Antibody Structure (IgG)


- Each chain has constant (C) and variable (V) regions
- The variable regions differ among antibody species in amino acid sequence—and therefore shape
- Antibodies bind antigens by the variable regions
- The variation in shape is responsible for differences in specificity of different antibody species




- It is estimated that there can be about 10^{11} different variable region amino acid sequences, and so about 10^{11} antibody specificities
- At a given time, about 10^9 are found in an individual
- Antibody diversity is generated by DNA rearrangements that occur during immune development



- There are several different types of antibody, each with specific functions
 - Two examples are **IgM** and **IgA**, which are important antibodies on mucosal surfaces




- “Neutralization” occurs when antibody binding to a target interferes directly with function



Human rhinovirus

Opsonization by Antibody



- Phagocytosis can be made much more efficient by antibody




- Complement fixation
- Antibody-dependent cytotoxicity
- Both depend on the binding of Ab to the outside of a cellular target to recruit effectors that kill the cell

- The primary effectors of CMI are cytotoxic T cells (killer T cells, CD8⁺ T cells, CTLs)
 - Activated macrophages also participate
- Cytotoxic T cells kill other cells
- The primary targets of cytotoxic T cells are usually pathogen-infected cells
- Like humoral immunity, CMI depends on specific recognition of an antigen by a protein: T-cell receptor


- Primary recognition molecule in CMI
- Similar in structure to antibody
 - Two chains
 - V and C regions
 - Membrane-bound




- TcR recognizes antigen by shape
- Recognition is of antigen fragments, bound to another specialized immune system protein, the **MHC I antigen**
- This is called “presentation”
- MHC I is found on the surface of essentially all cells



- The targets of CMI tend to be pathogen-infected cells
- Presentation is the consequence of a specific mechanism:
 - Processing
 - Intracellular loading of MHC I
 - Transport to the cell surface



- Antigen is presented
- Antigen is recognized by cytotoxic T cell
- The T cell releases pore-forming proteins
- The target cell dies, killing the internal pathogen



Humoral vs. Cell-Mediated Immunity

- Humoral immunity
 - Antibody-mediated
 - Effective in extracellular spaces
- CMI
 - Mediated by T cells
 - Effective against intracellular pathogens
 - Kills infected host cells




JOHNS HOPKINS
BLOOMBERG
SCHOOL *of* PUBLIC HEALTH

Section C


Induction of Adaptive Immunity

- Induction of the humoral and CMI responses involve parallel mechanisms:
 - Effectors arise from initially naïve precursor cells (B and T cells)
 - Precursors bear surface receptors with specificities generated at random (Ig, TcR)
 - Naïve precursors differentiate (acquire effector function) because of interaction between antigen and receptors
 - Development begins with an interaction between the pathogen and professional antigen-presenting cells (APCs)


- Situated for immediate interception of pathogens
- Biologically tuned to effectively initiate a response
- Specialized to deal with different threats




- Stationed in skin, gut, and circulation
- Phagocytic
- Surface receptors are preset to recognize common bacterial cell components
- Engulf, kill, process, and present
- Present using MHC II



- Stationed in lymph nodes and in the circulation
- Surface receptor is membrane-bound antibody
- Antibody specificities are randomly generated
- Antigens binding stimulates phagocytosis
- Antigens are processed and presented on MHC II



- Stationed in skin
- Particularly susceptible to infection by viruses
- Present internally-produced antigens on MHC I



- T cells are produced as naïve precursors
 - No effector function
 - Random TcR specificities
- Maturation is triggered by encountering a cell presenting a recognizable antigen
- Maturation of T cells involves primarily:
 - Acquisition of effector function
 - Proliferation of cells with specificities that suit the pathogen at hand (clonal expansion)

- Naïve T cells circulate, sampling the antigens presented on APCs
 - Sampling involves brief physical interaction between the antigen (in the context of MHC) and the T cell TcR
- If the antigen is not recognized, the interaction is short lived, and the T cell moves on

- If the antigen **is** recognized, binding is tight and long lived
 - Stimulatory signals are exchanged (cytokines)
 - The T cell proliferates
 - Effector mechanisms are developed
 - Memory cells are produced

Cytotoxic T Cells and Helper T Cells

- There are two kinds of T cells:
 - Cytotoxic T cells (T_C or CD8+)
 - Helper T cells (T_H or CD4+)
- These differ in function and therefore develop different effector functions
 - T_C kills virus infected cells and develops cytotoxic mechanisms discussed earlier
 - T_H assists in the immune response (below) and develops "helper" mechanisms (increased ability to secrete cytokines)

- T_H and T_C cells arise similarly—but from different naïve precursors
- Also, T_C development is stimulated by antigen presented on MHC I by dendritic cells
- T_H by antigen presented on MHC II

- Antibodies are the products of plasma cells, which mature from B cells
- Naïve B cells with random surface antibody specificities circulate, sampling the antigens present
- If an antigen recognized by the naïve B cell is encountered, its bind is internalized, and it is presented on MHC II
 - Modest proliferation also occurs, and partial activation toward the plasma cell state
- The B cell is now primed for differentiation, needing only help from a T_H cell

- The primed B cell continues to circulate, presenting its processed antigen to passing T cells
 - Since it presents on MHC II, only T_H cells are interested
- When a cognate T_H cell is finally encountered, signals are exchanged (as for T-cell maturation above)
 - Cell proliferation occurs
 - Differentiation to plasma cells and IgG production begins
 - ▶ (Refinement of specificity)
 - Memory cells are produced

Secondary Immune Response

- Arises from memory cells
- Arises quickly because the activation steps have occurred and need not be repeated
- Is large because of the increased number of starting cells



JOHNS HOPKINS
BLOOMBERG
SCHOOL *of* PUBLIC HEALTH

Section D

Poliovirus Pathogenesis: A Review

- Transmission by fecal-oral route via contaminated water
- Primary replication/multiplication is in lymphoid cells (specialized cells of the immune system), especially in the gut
- Virus is shed primarily into the gut and is excreted in the feces
- Some virus also enters the blood and reaches other susceptible cells; these include anterior horn cells (motor neurons), which innervate muscle
- Destruction of these cells can result in paralysis
 - *Disease is not a consequence of an essential step in the virus's life cycle*

- Two polio vaccines were developed with support from the March of Dimes campaign initiated in 1938 and sponsored by President Franklin Roosevelt, a paralytic polio victim
 1. Killed virus (Salk), licensed in 1955
 2. Attenuated live virus (Sabin), licensed in 1962

- The two vaccines have very different immune consequences
- What immunity is induced by each vaccine?
 - What APCs are initially involved? how do they present antigen?
 - What T cells does each stimulate?
 - What sort of immunity does each ultimately produce?

- What protection is conferred by each vaccine?
 - Against disease?
 - Against viral replication?
- Does each of these vaccines protect an individual against disease?

- What practical public health advantages does each vaccine have?
- What is current U.S. polio vaccine policy?